Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

88 results about "Golgi apparatus" patented technology

The Golgi apparatus, also known as the Golgi complex, Golgi body, or simply the Golgi, is an organelle found in most eukaryotic cells. It was identified in 1897 by the Italian scientist Camillo Golgi and named after him in 1898.

Intracellular organelle peptide targeted enzyme substrates

This invention relates to substrates and methods for the visualization of intracellular organelles, such as the lysosome, peroxiosome, nucleus, Endoplasmic Reticulum and Golgi Apparatus, based upon organelle enzyme activity. Such compounds represent a novel combination of chemically distinct enzyme substrates with targeting and detection substrates which are activated by enzyme activity inside target organelles to produce a detectable signal. The organelle targeted enzyme substrates of this invention are designed to provide high fluorescence at lower pH values found in some organelles and can be used for monitoring enzyme activity inside cells at very low concentrations.
Owner:MARKER GENE TECH

Genetically modified somatic cells for sustained secretion of lysosomal proenzymes deficient in lysosomal storage disorders

InactiveUS20060188975A1Avoids adverse immunological side effectAvoids renal clearance problemNervous disorderCell receptors/surface-antigens/surface-determinantsProgenitorZymogen
The invention relates to various methods of treating lysosomal storage disorders using somatic cells and methods of delivering therapeutic enzymes. More particularly, gain-of-function or loss-of-function mutations in components of the intracellular Golgi to lysosome sorting pathway are used to enhance secretion of one or more lysosomal enzymes in somatic cells, thereby providing treatment for lysosomal storage disorders, particularly in neuronal cells. In addition, homologous recombination may be used to engineer therapeutically useful cells, for example, somatic cells, such as, glial progenitor cells, mesenchymal stem cells and astrocyte precursor cells, to enhance secretion of one or more lysosomal enzymes.
Owner:Q THERAPEUTICS

Specific interaction of dentritic cell factor 1 (DCF1) genes and transmembrane protein 59 like (TMEM 59 L) genes

The invention relates to specific interaction of a dentritic cell factor 1 (DCF1) genes and transmembrane protein 59 like (TMEM 59 L) genes. Under the overexpression condition of the DCF1 and the TMEM 59 L, amyloid precursor protein (APP) can be highly and specifically inhibited from separating from golgi apparatus, the transportation of GDP dissociation inhibitor 1 (GDI1) and GDP dissociation inhibitor 2 (GDI2) are partially inhibited, the transportation of beta-site APP cleaving enzyme 2 (BACE2) protein is not inhibited, and a new drug target is provided for diagnosing and treating the Alzheimer disease.
Owner:SHANGHAI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products